MedPath

Jiangxi Synergy Pharmaceutical Co.,Ltd.

🇨🇳China
Ownership
-
Established
2004-04-20
Employees
1.3K
Market Cap
-
Website
http://www.jxsynergy.com
Introduction

The company was founded in 2004 and is mainly engaged in the production of APIs and intermediates. The production capacity and product quality of the main varieties are at the leading level in China. The company's main business is R&D, production and sales of chemical raw materials and pharmaceutical intermediates. The main products are gabapentin APIs, rebapide APIs, aceclofenac APIs, celecoxib APIs, candesartan esters APIs, azisartan APIs, sartan intermediates, dabigatran APIs, tigrello APIs, apixaban APIs, rivaroxaban APIs, vigagliptin APIs, engglizin APIs, venlafaxacin hydrochloride APIs, agomelatine APIs, fibusastat APIs, and mirabelone APIs. Company honors: Jiangsu Intellectual Property Advantage Enterprise, 2015 Advanced Foreign Trade Export Enterprise, A-grade Credit Enterprise, High-tech Enterprise Certificate, etc.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

5

NMPA:5

Drug Approvals

Vildagliptin Tablets

Product Name
维格列汀片
Approval Number
国药准字H20253048
Approval Date
Jan 2, 2025
NMPA

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20249409
Approval Date
Nov 15, 2024
NMPA

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20249407
Approval Date
Nov 15, 2024
NMPA

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20249408
Approval Date
Nov 15, 2024
NMPA

Venlafaxine Hydrochloride

Product Name
盐酸文拉法辛
Approval Number
国药准字H20084576
Approval Date
Nov 22, 2018
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.